Aarti Drugs LimitedQ1 FY27 Results & Financial Update
Aarti Drugs Limited: Q1 FY27 consolidated results and company financials – revenue ₹702.78 Cr, PAT ₹50.13 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Aarti Drugs price & chart
Market price₹387.85
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Aarti Drugs Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the first quarter of fiscal 2027 ended June 30, 2026, Aarti Drugs reported consolidated total revenue of Rs. 703.59 crore, reflecting a 19% year-on-year expansion compared to Rs. 590.80 crore in the corresponding period of the previous year.
Consolidated EBITDA reached Rs. 96.90 crore, recording a 30% year-on-year growth. The EBITDA margin expanded by 120 basis points year-on-year to 13.8%, supported by favorable product mix optimization and improved operating efficiencies across production units.
On a standalone basis, revenue reached Rs. 627.60 crore, representing a 20% year-on-year increase and accounting for approximately 89% of consolidated revenues. Domestic sales within the standalone business contributed 68% while export markets accounted for 32%.
Profit after tax was ₹50.13 Cr for the reported quarter. EPS was ₹5.49 for the reported quarter.
01 · Business model
What does Aarti Drugs do?
Aarti Drugs Limited is a Mumbai-based diversified and fully integrated pharmaceutical enterprise with core operations spanning Active Pharmaceutical Ingredients (APIs), pharma intermediates, specialty chemicals, and formulations.
The company operates 14 manufacturing facilities across India—10 located in Maharashtra, 3 in Gujarat, and 1 dedicated formulation plant in Himachal Pradesh operated through its wholly owned subsidiary, Pinnacle Life Science Private Limited.
Aarti Drugs maintains global leadership positions across several major API molecules, including being the world's largest producer of Nimesulide, Ketoconazole, Metronidazole Benzoate, Tinidazole, and the fluoroquinolones group, alongside a major manufacturing footprint in Metformin.
The company's commercial reach spans over 100 countries across six continents, supported by a robust R&D infrastructure anchored by dedicated centers at Tarapur and Turbhe focusing on process chemistry, complex generics, and regulated market filings.
02 · Historical context
What shaped the business before this quarter
The company expanded into the formulations segment in 2014 through the establishment of its 100% subsidiary, Pinnacle Life Science Private Limited.
Aarti Drugs surpassed a consolidated turnover of Rs. 2,000 crore and recorded a Profit After Tax exceeding Rs. 200 crore.
Revenue growth in preceding years faced headwinds from industry-wide oversupply and sharp API price erosion driven by excessive dumping from China, contrasting with steady underlying volume growth.
The company completed capital expenditure for greenfield projects at Sayakha (Gujarat) and Tarapur, alongside entering into an agreement with Prozeal Green Power Private Limited for setting up captive solar power plants.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹702.78 Cr |
| Total income | ₹703.59 Cr |
| Profit before tax | ₹69.24 Cr |
| Profit after tax | ₹50.13 Cr |
| EPS | ₹5.49 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Topline growth was underpinned by a combination of volume expansion and a recovery in pricing realizations across the API and specialty chemicals portfolios compared to depressed levels in the previous year.
Specialty chemicals demonstrated robust expansion, surging 150% year-on-year to Rs. 82.60 crore in Q1 FY27 from Rs. 33.10 crore in Q1 FY26.
The API segment, which forms the primary revenue engine, generated Rs. 510.40 crore, up 11% from Rs. 458.20 crore in Q1 FY26.
Within the standalone business, domestic revenues grew 25% year-on-year, while export revenues registered a 12% increase.
What drove margins
Gross profit for the quarter rose 27% year-on-year to Rs. 276.00 crore, driving gross margin up by 250 basis points to 39.3% from 36.8% in Q1 FY26.
EBITDA margin expanded by 120 basis points year-on-year to 13.8%, aided by operational efficiencies, backward integration benefits, and product mix optimization.
Margins were partially impacted by an additional expense of approximately Rs. 2.00 crore arising from a CWIP write-off included within other expenses.
05 · Demand, customers & order book
Where demand is coming from
Aarti Drugs maintains a highly diversified customer base where the largest domestic client accounts for approximately 4% of domestic sales and the top 10 clients account for about 25%; in export markets, the largest client represents approximately 7% and the top 10 clients represent about 27%.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
API revenues reached Rs. 510.40 crore in Q1 FY27 (up 11% YoY). Within API sales, anti-biotics contributed 35.0%, anti-diabetics 18.2%, anti-protozoals 18.5%, anti-inflammatories 11.9%, anti-fungals 10.2%, and other categories accounted for 6.1%.
Formulation segment revenue stood at Rs. 86.20 crore (consolidated) and Rs. 81.60 crore (standalone, up 8% YoY), with export markets contributing 74% of formulation revenues.
Specialty chemicals revenue jumped to Rs. 82.60 crore (up 150% YoY), while intermediates and others contributed Rs. 24.30 crore (up 26% YoY).
Geography and market mix
For the standalone business, domestic markets accounted for 68% of revenue and exports represented 32% during Q1 FY27.
The company maintains commercial presence across more than 100 countries spanning six continents, with Asia, North America, Europe, Latin America, and Africa forming key export destinations.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The Sayakha facility continued its planned ramp-up during the quarter, operating at nearly 65% utilization and contributing to the company's backward integration capabilities in methylamines and derivatives.
Total reaction capacity across manufacturing units exceeds 1,300 KL, supporting multi-step synthesis and fractionations ranging from kilogram to multi-ton scales.
Projects, capex and execution
The company is expanding its oral solid dosage (OSD) capabilities through brownfield and adjacent plot developments in Baddi, Himachal Pradesh, which is expected to double its production capacity.
An additional 800 TPM brownfield expansion for anti-diabetic APIs is underway, targeting USFDA markets with construction completion expected within 6 to 8 months.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Management continues to execute a strategic pivot toward scaling regulated market sales by leveraging USFDA, UK-MHRA, and EDQM approvals, supported by approximately 330 regulatory filings across 16 targeted geographies.
Ongoing investments in greenfield facilities such as Sayakha Amines and Tarapur Salicylic acid enhance internal sourcing of key raw materials like methylamines (DMA, MMA, TMA) for Metformin and other APIs.
09 · Reported developments
What changed operationally
Specialty chemicals segment revenue registered a 150% year-on-year increase to Rs. 82.60 crore.
10 · Pressure points & risks
What is not going smoothly
Reported PAT declined by 7% year-on-year to Rs. 50.13 crore due to a high base effect in Q1 FY26 which included a ~Rs. 15 crore principal tax refund.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
The company maintains a strong balance sheet with low leverage, supported by steady cash generation and manageable debt levels.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Regulatory Approvals
The company's facilities continue to hold key international approvals including USFDA and UK-MHRA, supporting ongoing expansion in regulated markets.
13 · Key Q&A
The quarter, answered directly
What does Aarti Drugs do?
Aarti Drugs Limited is a Mumbai-based diversified and fully integrated pharmaceutical enterprise with core operations spanning Active Pharmaceutical Ingredients (APIs), pharma intermediates, specialty chemicals, and formulations.
What is the clearest takeaway from Q1 FY27?
For the first quarter of fiscal 2027 ended June 30, 2026, Aarti Drugs reported consolidated total revenue of Rs. 703.59 crore, reflecting a 19% year-on-year expansion compared to Rs. 590.80 crore in the corresponding period of the previous year.
What drove revenue or demand?
Topline growth was underpinned by a combination of volume expansion and a recovery in pricing realizations across the API and specialty chemicals portfolios compared to depressed levels in the previous year.
What mattered most for margins or profitability?
Gross profit for the quarter rose 27% year-on-year to Rs. 276.00 crore, driving gross margin up by 250 basis points to 39.3% from 36.8% in Q1 FY26.
What changed operationally beyond the headline numbers?
The Sayakha facility continued its planned ramp-up during the quarter, operating at nearly 65% utilization and contributing to the company's backward integration capabilities in methylamines and derivatives.
What are the main pressure points disclosed for the quarter?
Reported PAT declined by 7% year-on-year to Rs. 50.13 crore due to a high base effect in Q1 FY26 which included a ~Rs. 15 crore principal tax refund.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Sayakha Utilization: Monitor the further ramp-up and utilization rates of the Sayakha facility beyond the current ~65% level.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.